← All trials
NCT05245734
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 8, 2022
- Primary completion
- Jan 31, 2024
- Completion date
- Mar 31, 2024
- First posted
- Feb 18, 2022
- Last posted
- Jun 24, 2022
- Enrollment
- 281
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Biopharma Plasma LLCLead sponsor
- Government of UkraineCollaborator
- Ivano-Frankivsk National Medical UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.